3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 4
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Other hematologic neoplasm
2
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Temozolomide
62
Cyclophosphamide
60
Radiotherapy
48
Doxorubicin
36
Filgrastim
26
Radiation
24
Irinotecan
24
fludarabine
23
Gemcitabine
23
Magnetic Resonance Spectroscopy
21
Imatinib Mesylate
19
Etoposide
18
pembrolizumab
16
Cisplatin
15
Carboplatin
15
Biopsy
15
Bevacizumab
15
Specimen Handling
14
fludarabine phosphate
12
Nivolumab
12
Leucovorin
12
Ipilimumab
12
Granulocyte Colony-Stimulating Factor
12
Chemotherapy, Adjuvant
12
pazopanib
11
Vincristine
11
Ifosfamide
11
Melphalan
10
Erlotinib Hydrochloride
10
Docetaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
pegylated granulocyte colony-stimulating factor
×
Sarcoma
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled